详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

A Multicenter Survey of One Year Survival Among Chinese Patients with Advanced Nonsquamous NonSmall Cell Lung Cancer (CTONG1506)

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Sichuan Cancer Hospital, Cheng Du/CN [2]Guangdong General Hospital., Guangzhou/CN [3]Nanjing General Hospital of Nanjing Military Command, Nanjing/CN [4]Zhongshan Hospital, Shanghai/CN [5]Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin/CN [6]Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou/CN [7]Hunan Cancer Hospital, Chang Sha/CN [8]The Affiliated Hospital of Qingdao University, Qing Dao/CN [9]Department of Oncology, General Hospital of Chinese PLA, Beijing/CN [10]Shanxi Cancer Hospital. Taiyuan, Taiyuan/CN [11]Tianjin/CN [12]The People’S Hospital of Guangxi Zhuang Autonomous Region, Nanning/CN [13]Eli Lilly and Company, Shanghai/CN [14]Shanghai Centenial Scientific Co., Shanghai/ CN [15]Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhgou/CN

出处：

DOI：

ISSN：

关键词： NSCLC real world survival

语种：

WOS：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 1 区

医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2018]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21 最新[2023版] 16.5 最新五年平均 12.46 出版当年[2018版] 8.824 出版当年五年平均 10.34 出版前一年[2017版] 13.357 出版后一年[2019版]

第一作者：

第一作者机构： [1]Sichuan Cancer Hospital, Cheng Du/CN

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]A Multicenter Survey of One Year Survival Among Chinese Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (CTONG1506) [2]Real-World Treatment Patterns in Chinese Stage III NSCLC Patients - A Prospective, Non-Interventional Study (MOOREA trial) [3]Preoperative Radiotherapy Decision-Tree for Rectal Cancer Patients: A Real-World Analysis Based on the Swedish Colorectal Cancer Registry [4]Outcomes of radiotherapy combined with systemic therapy for stage IV NSCLC: A real-world study. [5]Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study [6]Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study [7]A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer [8]Outcomes of radiotherapy combined with systemic therapy for stage IV NSCLC: A real-world study [9]Real-World Treatment Patterns in Chinese Stage III NSCLC Patients - A Prospective, Non-Interventional Study (MOOREA trial) [10]Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.